Naltrexone Accord (Naltrexone Hydrochloride)

Naltrexone Hydrochloride, the active ingredient in Naltrexone Accord, is an opioid antagonist presented as an oral tablet for systemic use. It is employed to reduce cravings and prevent relapse in individuals with alcohol dependence and to support abstinence in patients dependent on opioids.

GNH USA supplies Naltrexone Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Naltrexone Accord is an opioid antagonist used in the management of substance‑use disorders.

- Alcohol dependence: helps maintain abstinence and reduces relapse risk. - Opioid dependence: supports opioid‑free status after detoxification. - Alcohol use disorder: assists in decreasing cravings when combined with psychosocial support.

Naltrexone may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe allergic reactions, including anaphylaxis - Mood changes such as depression or suicidal ideation

When prescribing Naltrexone Accord, clinicians should consider several safety and handling precautions.

- Assess liver function: evaluate baseline hepatic enzymes before initiating therapy. - Monitor for opioid withdrawal: ensure the patient is opioid‑free for at least 7‑10 days. - Avoid use in acute hepatitis: contraindicated in active severe liver disease. - Educate patients on avoiding opioid analgesics: concurrent use may precipitate withdrawal. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Naltrexone can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Opioid analgesics: concurrent use blocks analgesia and may precipitate withdrawal. - Disulfiram: combined use may increase hepatotoxic risk.

Moderate Interactions (Monitor Closely): - Alcohol: concurrent use may enhance hepatotoxicity. - Benzodiazepines: may increase sedation when withdrawal symptoms are present. - CYP2D6 inhibitors: may modestly raise naltrexone plasma levels.